Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals logoIonis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IONS
  • CUSIP: 46433010
  • Web:
  • Market Cap: $7.94 billion
  • Outstanding Shares: 124,354,000
Average Prices:
  • 50 Day Moving Avg: $54.75
  • 200 Day Moving Avg: $49.79
  • 52 Week Range: $24.58 - $64.19
  • Trailing P/E Ratio: 293.99
  • Foreward P/E Ratio: 912.14
  • P/E Growth: -8.80
Sales & Book Value:
  • Annual Revenue: $485.73 million
  • Price / Sales: 16.35
  • Book Value: $1.74 per share
  • Price / Book: 36.70
  • EBITDA: $80.88 million
  • Net Margins: 5.25%
  • Return on Equity: 15.52%
  • Return on Assets: 2.59%
  • Debt-to-Equity Ratio: 2.47%
  • Current Ratio: 5.03%
  • Quick Ratio: 5.00%
  • Average Volume: 1.24 million shs.
  • Beta: 3.12
  • Short Ratio: 7.99

Frequently Asked Questions for Ionis Pharmaceuticals (NASDAQ:IONS)

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.03. The business earned $104.15 million during the quarter, compared to analysts' expectations of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The company's quarterly revenue was up 170.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.47) EPS. View Ionis Pharmaceuticals' Earnings History.

When will Ionis Pharmaceuticals make its next earnings announcement?

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Ionis Pharmaceuticals.

Where is Ionis Pharmaceuticals' stock going? Where will Ionis Pharmaceuticals' stock price be in 2017?

14 brokerages have issued twelve-month target prices for Ionis Pharmaceuticals' stock. Their predictions range from $18.00 to $69.00. On average, they expect Ionis Pharmaceuticals' share price to reach $49.62 in the next twelve months. View Analyst Ratings for Ionis Pharmaceuticals.

What are analysts saying about Ionis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (10/17/2017)
  • 2. BMO Capital Markets analysts commented, " We maintain our Outperform rating, but decrease our price target to $59 from $63, following Phase III volanesorsen FCS data that showed strong efficacy, but higher frequency of platelet monitoring to maintain treatment. While we believe volanesorsen will be approved, biweekly monitoring and injection site reactions (ISRs) could limit patient adherence to therapy, leading us to decrease our compliance/ persistence rate to 75% from 85%. Our market share assumptions remain unchanged, given the disease burden and limited treatment options. We estimate Volanesorsen WW peak sales of $820 million." (3/7/2017)
  • 3. Needham & Company LLC analysts commented, "Akcea, a wholly owned subsidiary of Ionis Pharmaceuticals, reported that volanesorsen met its primary endpoint of triglyceride lowering in the Phase III APPROACH study in patients with familial chylomicronemia syndrome (FCS). A surprise positive, the study also demonstrated significant reductions in pancreatic attacks and abdominal pain. However, IONS shares are reacting negatively this morning because of the reported incidence of discontinuations for thrombocytopenia. We view the sell off as an over reaction considering that the platelet reductions are disease related and rgw study discontinuations stopped occurring after monitoring was implemented. We maintain our Buy rating on IONS." (3/6/2017)
  • 4. Cowen and Company analysts commented, "Ionis provided an update on its pipeline of ~40 antisense drug candidates." (1/6/2017)

Are investors shorting Ionis Pharmaceuticals?

Ionis Pharmaceuticals saw a decline in short interest in September. As of September 15th, there was short interest totalling 10,235,812 shares, a decline of 11.1% from the August 31st total of 11,514,444 shares. Based on an average daily trading volume, of 948,653 shares, the short-interest ratio is currently 10.8 days. Currently, 8.3% of the shares of the stock are sold short.

Who are some of Ionis Pharmaceuticals' key competitors?

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:

  • Stanley T. Crooke M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Elizabeth L. Hougen, Chief Financial Officer, Senior Vice President - Finance
  • B. Lynne Parshall J.D., Chief Operating Officer, Corporate Secretary, Director
  • Patrick R. O'Neil Esq., Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary
  • C. Frank Frank Bennett Ph.D., Senior Vice President - Antisense Research
  • Richard S. Geary Ph.D., Senior Vice President - Development
  • Brett P. Monia Ph.D., Senior Vice President - Drug Discovery and Corporate Development
  • Sarah Boyce, Chief Business Officer
  • Spencer R. Berthelsen M.D., Independent Director
  • Breaux B. Castleman, Independent Director

How do I buy Ionis Pharmaceuticals stock?

Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $63.85.

MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  382 (Vote Underperform)
Total Votes:  745
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 6 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.29)
Consensus Price Target: $49.62 (22.29% downside)
Consensus Price Target History for Ionis Pharmaceuticals (NASDAQ:IONS)
Price Target History for Ionis Pharmaceuticals (NASDAQ:IONS)
Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017Needham & Company LLCReiterated RatingBuy$64.00N/AView Rating Details
10/13/2017Stifel NicolausReiterated RatingHold$50.00N/AView Rating Details
10/6/2017Goldman Sachs Group, Inc. (The)Reiterated RatingSell -> Sell$30.00N/AView Rating Details
10/2/2017BMO Capital MarketsReiterated RatingOutperform$69.00MediumView Rating Details
9/21/2017Barclays PLCLower Price TargetEqual Weight$55.00 -> $52.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$65.00LowView Rating Details
8/14/2017LaidlawReiterated RatingBuy$65.00LowView Rating Details
8/10/2017Jefferies Group LLCReiterated RatingUnderperform$17.00 -> $18.00HighView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$57.00HighView Rating Details
5/22/2017Cowen and CompanyReiterated RatingMarket PerformLowView Rating Details
5/17/2017Leerink SwannReiterated RatingOutperform$47.00 -> $45.00MediumView Rating Details
5/10/2017Piper Jaffray CompaniesSet Price TargetBuy$66.00 -> $51.00LowView Rating Details
1/5/2017Janney Montgomery ScottSet Price TargetHold$44.00N/AView Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHold$35.00N/AView Rating Details
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
8/2/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$37.00 -> $37.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)
Earnings by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Earnings History by Quarter for Ionis Pharmaceuticals (NASDAQ IONS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.06)N/AView Earnings Details
8/8/2017Q2 2017($0.06)($0.09)$93.29 million$104.15 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.10)$0.03$86.03 million$110.30 millionViewListenView Earnings Details
2/28/2017Q416($0.20)$0.33$97.47 million$160.30 millionViewListenView Earnings Details
11/9/2016Q316$0.07$0.06$114.65 million$110.90 millionViewListenView Earnings Details
8/9/2016Q216($0.52)($0.47)$38.52 million$38.50 millionViewN/AView Earnings Details
5/4/2016Q116($0.50)($0.52)$36.21 million$36.90 millionViewN/AView Earnings Details
2/25/2016Q415($0.47)($0.59)$49.32 million$51.60 millionViewListenView Earnings Details
11/9/2015Q315($0.31)($0.30)$52.93 million$49.10 millionViewN/AView Earnings Details
8/4/2015Q215$0.29$0.29$114.93 million$120.40 millionViewN/AView Earnings Details
5/5/2015Q115($0.19)($0.14)$52.74 million$62.60 millionViewN/AView Earnings Details
2/27/2015Q414$0.12$0.25$74.58 million$84.90 millionViewN/AView Earnings Details
11/7/2014Q314($0.20)($0.23)$45.79 million$44.10 millionViewN/AView Earnings Details
8/4/2014Q214($0.12)($0.10)$45.60 million$57.08 millionViewN/AView Earnings Details
5/6/2014Q114($0.23)($0.27)$35.12 million$28.20 millionViewN/AView Earnings Details
2/28/2014Q413($0.17)($0.21)$34.20 million$42.25 millionViewN/AView Earnings Details
11/5/2013Q313($0.27)($0.21)$19.82 million$23.60 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.21)($0.09)$26.76 million$38.10 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.02)($0.02)$45.24 million$43.36 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.23)($0.03)$15.78 million$19.90 millionViewListenView Earnings Details
11/6/2012Q312($0.26)($0.37)$23.11 million$11.60 millionViewN/AView Earnings Details
8/6/2012($0.08)($0.01)ViewN/AView Earnings Details
5/8/2012($0.28)($0.24)ViewN/AView Earnings Details
2/29/2012($0.13)($0.20)ViewN/AView Earnings Details
11/7/2011($0.20)($0.27)ViewN/AView Earnings Details
8/4/2011($0.22)($0.18)ViewN/AView Earnings Details
5/5/2011($0.19)($0.20)ViewN/AView Earnings Details
2/28/2011($0.22)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)
2017 EPS Consensus Estimate: $0.13
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.06)$0.16$0.05
Q2 20172($0.38)$0.19($0.10)
Q3 20172$0.07$0.22$0.15
Q4 20172($0.17)$0.23$0.03
(Data provided by Zacks Investment Research)


Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Ionis Pharmaceuticals (NASDAQ:IONS)
Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 89.24%
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/13/2017Richard S GearySVPSell8,268$60.00$496,080.00View SEC Filing  
10/13/2017Stanley T CrookeChairmanSell16,500$59.46$981,090.00View SEC Filing  
10/5/2017Patrick R O'neilSVPSell1,000$55.00$55,000.00View SEC Filing  
10/4/2017Stanley T CrookeChairmanSell27,500$52.89$1,454,475.00View SEC Filing  
10/2/2017Stanley T CrookeCEOSell15,000$52.00$780,000.00View SEC Filing  
9/6/2017Patrick R O'neilSVPSell1,000$55.00$55,000.00View SEC Filing  
7/24/2017C Frank BennettSVPSell10,000$59.29$592,900.00View SEC Filing  
7/20/2017Stanley T CrookeChairmanSell11,000$55.35$608,850.00View SEC Filing  
7/19/2017Ionis Pharmaceuticals IncMajor ShareholderBuy3,125,000$8.00$25,000,000.00View SEC Filing  
7/17/2017Stanley T CrookeChairmanSell16,500$52.45$865,425.00View SEC Filing  
7/3/2017Brett P MoniaSVPSell309$51.35$15,867.15View SEC Filing  
7/3/2017Stanley T CrookeChairmanSell16,500$52.10$859,650.00View SEC Filing  
6/1/2017Patrick R O'neilSVPSell70$48.00$3,360.00View SEC Filing  
5/1/2017Patrick R O'neilSVPSell650$48.75$31,687.50View SEC Filing  
4/25/2017Stanley T CrookeChairmanSell16,500$47.81$788,865.00View SEC Filing  
4/24/2017Patrick R O'neilSVPSell500$45.00$22,500.00View SEC Filing  
4/19/2017Stanley T CrookeChairmanSell5,500$43.25$237,875.00View SEC Filing  
4/13/2017Stanley T CrookeChairmanSell22,000$40.69$895,180.00View SEC Filing  
4/12/2017Patrick R O'neilSVPSell1,000$40.07$40,070.00View SEC Filing  
3/3/2017C Frank BennettSVPSell5,000$55.00$275,000.00View SEC Filing  
3/1/2017B Lynne ParshallCOOSell4,625$49.26$227,827.50View SEC Filing  
3/1/2017Patrick R O'neilSVPSell1,500$49.29$73,935.00View SEC Filing  
2/6/2017Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
1/17/2017B Lynne ParshallCOOSell7,246$46.29$335,417.34View SEC Filing  
1/17/2017Brett P MoniaSVPSell2,502$46.29$115,817.58View SEC Filing  
1/17/2017Elizabeth L HougenCFOSell2,273$46.29$105,217.17View SEC Filing  
1/17/2017Sarah BoyceInsiderSell1,361$46.29$63,000.69View SEC Filing  
1/17/2017Stanley T CrookeCEOSell15,382$46.29$712,032.78View SEC Filing  
1/10/2017Stanley T CrookeChairmanSell13,200$49.25$650,100.00View SEC Filing  
1/4/2017Stanley T CrookeChairmanSell18,700$48.89$914,243.00View SEC Filing  
1/3/2017Brett P MoniaSVPSell309$48.60$15,017.40View SEC Filing  
12/20/2016Brett P MoniaSVPSell130$52.48$6,822.40View SEC Filing  
12/15/2016B Lynne ParshallCOOSell4,000$50.00$200,000.00View SEC Filing  
12/5/2016Elizabeth L HougenCFOSell2,500$46.05$115,125.00View SEC Filing  
12/5/2016Patrick R O'neilSVPSell350$45.00$15,750.00View SEC Filing  
12/1/2016B Lynne ParshallCOOSell12,500$42.23$527,875.00View SEC Filing  
11/14/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
11/11/2016Elizabeth L HougenSVPSell5,000$39.75$198,750.00View SEC Filing  
11/7/2016C Frank BennettSVPSell5,000$34.00$170,000.00View SEC Filing  
10/5/2016Stanley T CrookeChairmanSell11,000$36.61$402,710.00View SEC Filing  
9/27/2016Stanley T CrookeChairmanSell22,000$36.02$792,440.00View SEC Filing  
9/21/2016Stanley T CrookeChairmanSell22,000$35.50$781,000.00View SEC Filing  
9/1/2016B Lynne ParshallCOOSell12,500$29.88$373,500.00View SEC Filing  
5/31/2016Frederick T MutoDirectorSell12,500$22.31$278,875.00View SEC Filing  
4/6/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
4/6/2016Stanley T CrookeCEOSell11,000$46.13$507,430.00View SEC Filing  
3/31/2016Stanley T CrookeCEOSell11,000$40.74$448,140.00View SEC Filing  
3/23/2016Patrick R O'neilSVPSell1,000$45.40$45,400.00View SEC Filing  
1/19/2016B Lynne ParshallCOOSell5,192$41.46$215,260.32View SEC Filing  
1/19/2016C Frank BennettSVPSell2,110$41.46$87,480.60View SEC Filing  
1/19/2016Elizabeth L. HougenCFOSell1,899$41.46$78,732.54View SEC Filing  
1/19/2016Sarah BoyceinsiderSell872$41.46$36,153.12View SEC Filing  
1/19/2016Stanley T. CrookeCEOSell13,401$41.46$555,605.46View SEC Filing  
1/5/2016Stanley T. CrookeCEOSell5,500$62.10$341,550.00View SEC Filing  
1/4/2016B Lynne ParshallCOOSell809$61.05$49,389.45View SEC Filing  
1/4/2016Brett P. MoniaSVPSell127$61.00$7,747.00View SEC Filing  
1/4/2016Stanley T. CrookeCEOSell11,000$61.05$671,550.00View SEC Filing  
12/16/2015C Frank BennettSVPSell7,909$57.41$454,055.69View SEC Filing  
12/1/2015Patrick R. O'neilSVPSell1,000$61.50$61,500.00View SEC Filing  
11/11/2015Joseph Klein IIIDirectorSell6,875$64.18$441,237.50View SEC Filing  
11/10/2015C Frank BennettSVPSell5,000$64.00$320,000.00View SEC Filing  
11/6/2015C Frank BennettSVPSell5,000$56.00$280,000.00View SEC Filing  
11/3/2015Patrick R. O'neilSVPSell1,000$51.95$51,950.00View SEC Filing  
10/23/2015Stanley T. CrookeCEOSell44,000$43.85$1,929,400.00View SEC Filing  
10/2/2015B Lynne ParshallCOOSell12,436$40.75$506,767.00View SEC Filing  
7/6/2015B Lynne ParshallCOOSell6,218$57.01$354,488.18View SEC Filing  
7/6/2015Stanley T CrookeCEOSell5,000$57.01$285,050.00View SEC Filing  
7/1/2015B Lynne ParshallCOOSell6,218$57.56$357,908.08View SEC Filing  
7/1/2015Stanley T CrookeCEOSell6,175$57.56$355,433.00View SEC Filing  
6/8/2015Brett P MoniaSVPSell7,600$66.22$503,272.00View SEC Filing  
4/7/2015B Lynne ParshallCOOSell5,565$63.07$350,984.55View SEC Filing  
4/7/2015Stanley T CrookeCEOSell22,377$63.07$1,411,317.39View SEC Filing  
3/24/2015C Frank BennettSVPSell15,000$70.61$1,059,150.00View SEC Filing  
3/19/2015Elizabeth L HougenCFOSell10,000$73.33$733,300.00View SEC Filing  
3/19/2015Patrick R O'neilSVPSell30,525$74.85$2,284,796.25View SEC Filing  
3/2/2015Joseph H WenderDirectorSell7,000$65.97$461,790.00View SEC Filing  
1/27/2015Stanley T CrookeCEOSell11,000$72.93$802,230.00View SEC Filing  
1/16/2015B Lynne ParshallCOOSell4,093$67.96$278,160.28View SEC Filing  
1/16/2015Elizabeth L HougenCFOSell1,291$67.96$87,736.36View SEC Filing  
1/16/2015Richard S GearySVPSell1,543$67.96$104,862.28View SEC Filing  
1/16/2015Stanley T CrookeCEOSell9,054$67.96$615,309.84View SEC Filing  
1/9/2015Stanley T CrookeCEOSell11,000$73.57$809,270.00View SEC Filing  
1/7/2015Stanley T CrookeCEOSell22,000$67.04$1,474,880.00View SEC Filing  
1/2/2015B Lynne ParshallCOOSell11,200$62.12$695,744.00View SEC Filing  
1/2/2015Patrick R O'neilSVPSell1,500$62.12$93,180.00View SEC Filing  
12/1/2014Patrick R O'neilSVPSell1,500$51.21$76,815.00View SEC Filing  
11/3/2014Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
10/30/2014B Lynne ParshallCOOSell11,071$45.12$499,523.52View SEC Filing  
10/23/2014Stanley T CrookeCEOSell14,600$42.22$616,412.00View SEC Filing  
10/3/2014Stanley T CrookeCEOSell36,000$38.52$1,386,720.00View SEC Filing  
10/1/2014Patrick R O'neilSVPSell1,500$38.04$57,060.00View SEC Filing  
10/1/2014Stanley T CrookeCEOSell20,000$37.91$758,200.00View SEC Filing  
8/27/2014C Frank BennettSVPSell5,000$40.53$202,650.00View SEC Filing  
8/13/2014Stanley T CrookeCEOSell15,500$35.45$549,475.00View SEC Filing  
8/12/2014Patrick R O'neilSVPSell1,500$35.00$52,500.00View SEC Filing  
8/1/2014Stanley T CrookeCEOSell16,000$30.53$488,480.00View SEC Filing  
7/31/2014Brett P MoniaSVPSell79$31.50$2,488.50View SEC Filing  
7/1/2014Patrick R O'neilSVPSell1,500$35.33$52,995.00View SEC Filing  
7/1/2014Stanley T CrookeCEOSell17,500$35.57$622,475.00View SEC Filing  
6/23/2014C Frank BennettSVPSell11,200$36.78$411,936.00View SEC Filing  
6/19/2014Stanley T CrookeCEOSell11,000$35.10$386,100.00View SEC Filing  
6/10/2014Stanley T CrookeCEOSell11,000$33.46$368,060.00View SEC Filing  
6/2/2014Frederick T MutoDirectorSell10,000$28.59$285,900.00View SEC Filing  
4/2/2014Stanley CrookeCEOSell8,800$43.65$384,120.00View SEC Filing  
1/30/2014B Lynne ParshallCOOSell89,510$49.49$4,429,849.90View SEC Filing  
1/24/2014Joseph Klein IIIDirectorSell10,313$48.66$501,830.58View SEC Filing  
1/22/2014Joseph WenderDirectorSell10,000$50.98$509,800.00View SEC Filing  
1/22/2014Richard GearySVPSell22,200$50.05$1,111,110.00View SEC Filing  
1/16/2014B Lynne ParshallCOOSell1,641$47.08$77,258.28View SEC Filing  
1/16/2014Stanley CrookeCEOSell3,527$47.08$166,051.16View SEC Filing  
1/8/2014Richard GearySVPSell15,000$40.45$606,750.00View SEC Filing  
1/8/2014Stanley CrookeCEOSell12,500$40.05$500,625.00View SEC Filing  
1/2/2014Stanley CrookeCEOSell31,500$39.35$1,239,525.00View SEC Filing  
12/26/2013B Lynne ParshallCOOSell37,811$40.91$1,546,848.01View SEC Filing  
12/24/2013B Lynne ParshallCOOSell70,000$41.49$2,904,300.00View SEC Filing  
12/20/2013Joseph WenderDirectorSell19,731$39.58$780,952.98View SEC Filing  
12/5/2013C Frank BennettSVPSell10,000$39.92$399,200.00View SEC Filing  
11/26/2013Joseph WenderDirectorSell10,000$36.63$366,300.00View SEC Filing  
9/20/2013B Lynne ParshallCOOSell90,000$35.43$3,188,700.00View SEC Filing  
9/20/2013Brett MoniaSVPSell68,281$34.21$2,335,893.01View SEC Filing  
9/20/2013Stanley CrookeCEOSell58,740$35.19$2,067,060.60View SEC Filing  
9/19/2013C Frank BennettSVPSell10,000$35.02$350,200.00View SEC Filing  
9/11/2013B Lynne ParshallCOOSell63,505$31.04$1,971,195.20View SEC Filing  
9/9/2013C Frank BennettSVPSell10,000$30.23$302,300.00View SEC Filing  
9/4/2013Patrick R O'neilSVPSell2,500$27.09$67,725.00View SEC Filing  
8/26/2013Brett MoniaSVPSell2,909$25.58$74,412.22View SEC Filing  
8/9/2013Joseph Klein IIIDirectorSell18,750$28.22$529,125.00View SEC Filing  
7/23/2013Stanley T CrookeCOOSell11,500$30.00$345,000.00View SEC Filing  
7/22/2013Stanley T CrookeCEOSell62,200$30.50$1,897,100.00View SEC Filing  
7/17/2013Stanley T CrookeCEOSell49,300$33.12$1,632,816.00View SEC Filing  
7/12/2013Stanley T CrookeCEOSell90,000$31.75$2,857,500.00View SEC Filing  
7/11/2013Richard S GearySVPSell9,000$31.90$287,100.00View SEC Filing  
7/9/2013Richard S GearySVPSell66,163$30.03$1,986,874.89View SEC Filing  
7/9/2013Stanley T CrookeCEOSell109,172$26.69$2,913,800.68View SEC Filing  
7/3/2013Richard S GearySVPSell5,000$29.02$145,100.00View SEC Filing  
7/1/2013Stanley T CrookeCEOSell50,683$27.65$1,401,384.95View SEC Filing  
6/26/2013Stanley T CrookeCEOSell90,000$26.73$2,405,700.00View SEC Filing  
6/25/2013Richard S GearySVPSell47,049$26.20$1,232,683.80View SEC Filing  
6/20/2013Joseph H WenderDirectorSell5,447$20.93$114,005.71View SEC Filing  
6/11/2013Brett P MoniaSVPSell9,375$23.76$222,750.00View SEC Filing  
5/30/2013Frederick T MutoDirectorSell10,000$21.96$219,600.00View SEC Filing  
1/16/2013Stanley T CrookeCEOSell1,460$14.00$20,440.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ionis Pharmaceuticals (NASDAQ:IONS)
Latest Headlines for Ionis Pharmaceuticals (NASDAQ:IONS)
DateHeadline logoIonis Pharmaceuticals, Inc. (IONS) SVP Sells $496,080.00 in Stock - October 17 at 7:28 PM logoStanley T. Crooke Sells 16,500 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock - October 17 at 7:26 PM logoIonis Presents New Data from NEURO-TTR Study and Highlights Programs from Its Neurological Disease Franchise at ... - PR Newswire (press release) - October 16 at 3:41 PM logoFeatured Company News - Ionis Pharma Commences Phase-1/2a Clinical Study of IONIS-MAPTRx for Patients with Alzheimer's Disease - October 16 at 3:41 PM logoBiogen Biomarkers Mark Way To Alzheimer's, Parkinson's Treatments - October 16 at 3:41 PM logoIonis Presents New Data from NEURO-TTR Study and Highlights Programs from Its Neurological Disease Franchise at ANA Congress - October 15 at 6:49 PM logoIonis Pharma (IONS) Commences Clinical Study of IONIS-MAPT Rx - - October 15 at 12:26 AM logoIonis Pharmaceuticals' (IONS) Hold Rating Reaffirmed at Stifel Nicolaus - October 14 at 1:30 PM logoIonis Pharma (IONS) Commences Clinical Study of IONIS-MAPT Rx - October 14 at 12:51 AM logoIonis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer's Disease - October 13 at 7:49 PM logoIonis Pharmaceuticals, Inc. (IONS) Given Consensus Rating of "Hold" by Brokerages - October 7 at 3:02 PM logoGoldman Sachs Group, Inc. (The) Reaffirms "Sell" Rating for Ionis Pharmaceuticals, Inc. (IONS) - October 7 at 12:58 AM logoETFs with exposure to Ionis Pharmaceuticals, Inc. : October 6, 2017 - October 6 at 11:46 PM logoIonis Pharmaceuticals, Inc. (IONS) SVP Sells $55,000.00 in Stock - October 6 at 8:16 PM logoToday's Research Reports on Trending Tickers: Ionis Pharmaceuticals and HTG Molecular Diagnostics - October 6 at 8:21 AM logoIonis Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating - October 6 at 12:41 AM logoIonis Pharmaceuticals, Inc. :IONS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017 - October 6 at 12:41 AM logo$129.33 Million in Sales Expected for Ionis Pharmaceuticals, Inc. (IONS) This Quarter - October 5 at 9:46 AM logoInsider Selling: Ionis Pharmaceuticals, Inc. (IONS) Chairman Sells 27,500 Shares of Stock - October 4 at 10:22 PM logoStanley T. Crooke Sells 15,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock - October 4 at 10:22 PM logoBreakfast Technical Briefing on Drug Makers Stocks -- Amarin, Endo, Ionis Pharma, and Teva Pharma - PR Newswire (press release) - October 4 at 5:49 PM logoIonis Pharmaceuticals, Inc. (IONS) Expected to Post Earnings of $0.02 Per Share - October 3 at 6:20 AM logoBMO Capital Markets Reiterates Outperform Rating for Ionis Pharmaceuticals, Inc. (IONS) - October 2 at 2:36 PM logoIonis Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IONS-US : October 2, 2017 - October 2 at 1:04 PM logoIonis Pharmaceuticals, Inc. (IONS) Sees Significant Decrease in Short Interest - September 29 at 1:28 AM logoAlnylam Is Entering 'New Chapter,' But Ionis Still Has A Chance - September 22 at 1:50 PM logoIonis Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IONS-US : September 22, 2017 - September 22 at 1:50 PM logoBarclays PLC Trims Ionis Pharmaceuticals, Inc. (IONS) Target Price to $52.00 - September 21 at 3:46 PM logoVoyager Therapeutics (VYGR) & Ionis Pharmaceuticals (IONS) Financial Comparison - September 20 at 4:14 PM logoIonis Pharmaceuticals, Inc. (IONS) Stock Rating Reaffirmed by Needham & Company LLC - September 17 at 8:58 AM logoAnalyzing Brainstorm Cell Therapeutics (BCLI) and Ionis Pharmaceuticals (IONS) - September 17 at 2:31 AM logoAkcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada - Nasdaq - September 12 at 4:41 PM logoAkcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada - September 12 at 4:41 PM logoIonis Pharmaceuticals, Inc. (IONS) Receives Average Recommendation of "Hold" from Analysts - September 12 at 2:50 PM logoIonis Pharmaceuticals, Inc. (IONS) Rating Reiterated by Stifel Nicolaus - September 12 at 11:22 AM logoIonis Pharma (IONS) Reports New Data from Clinical Program for IONIS-STAT3-2.5Rx (AZD9150) at ESCO 2017 - September 12 at 1:43 AM logoIonis Pharma (IONS) Reports New Data from Clinical Program for IONIS-STAT3-2.5Rx (AZD9150) at ESCO 2017 - - September 11 at 6:12 AM logoNew Data Presented at European Society for Medical Oncology Meeting Demonstrate Antitumor Activity with IONIS-STAT3-2.5 Rx in Combination with Imfinzi - September 11 at 6:12 AM logoIonis Pharmaceuticals, Inc. (IONS) Receives New Coverage from Analysts at Barclays PLC - September 10 at 5:16 PM logoNLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted - September 8 at 1:19 AM logoInsider Selling: Ionis Pharmaceuticals, Inc. (IONS) SVP Sells 1,000 Shares of Stock - September 7 at 10:24 PM logoBreaking Down Barclays' New Bullish Calls On Biotech - Benzinga - September 7 at 8:16 PM logoToday's Research Reports on Trending Tickers: Nektar Therapeutics and Ionis Pharmaceuticals Inc. - September 2 at 12:13 AM logoIonis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : September 1, 2017 - September 2 at 12:13 AM logoAkcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the US FDA - GlobeNewswire (press release) - September 1 at 1:00 AM logoTechnology Platforms and Research Programs Drive LGND’s Partnerships - August 31 at 7:58 PM logoIonis Pharma (IONS) Earns $40M Milestone from Biogen for SPINRAZA - August 31 at 6:15 AM logoIonis Earns $40 Million SPINRAZA Regulatory Milestone Payment from Biogen - August 31 at 6:15 AM logoIonis Recommends Shareholders Reject The Below-The-Market Mini-Tender Offer By TRC Capital Corporation - PR Newswire (press release) - August 25 at 10:26 PM logoMust-Know Developments for Ionis Pharmaceuticals - August 25 at 4:43 PM



Ionis Pharmaceuticals (IONS) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.